I work at the intersection of research strategy, institutional development, and early commercialization, with a focus on immunology, cancer research, partnerships, and company formation.
Current emphasis
Helping shape systems that move scientific ideas toward licensing, partnerships, and selectively, new companies.
Long-term direction
Evolving from institutional strategy into translational building and venture creation around high-value scientific IP.
About
I am a research strategy and development leader working in immunology and cancer research. My interests include scientific planning, external partnerships, translational infrastructure, and the early stages of commercialization.
A growing focus of my work is how institutions can do a better job of identifying promising intellectual property, de-risking it early, and creating clearer paths to licensing, partnership, or company formation.
Over time, I want to help build stronger systems that connect scientific discovery to durable external impact while returning meaningful value to the institutions and laboratories where that work begins.
What I am building toward
Connecting strong scientific discovery to real-world impact through commercialization planning, licensing strategy, and company formation.
Developing productive collaborations across academia, biotech, philanthropy, and emerging innovation ecosystems.
Leading research planning, scientific communications, and institutional strategy in immunology and cancer research.
Immunology and cancer research, early commercialization, spinout planning, and partnerships across academic and industry settings.
Writing
Occasional thinking on scientific strategy, AI in research, translational infrastructure, and how discovery becomes impact.
Chemical Biology Is Expanding the Proteome. AI Is Making It Usable.
The limiting factor in drug discovery is no longer access to the proteome. It is knowing what to do once you are inside it.
April 2026
The AI Inflection: Out with the Old and in with the Old
AI promises to transform research. The bottleneck, as always, is data and the humans who know what to do with it.
April 2026
All postsSelective collaborations and conversations
I am interested in thoughtful conversations around research strategy, translational development, licensing, early commercialization, and company-building around scientific IP.
Get in touch